ICER Eyes Gene Therapy: Category-wide Policy In Works As Spark Moves To Approval

Institute for Clinical and Economic Review launches value assessment of Spark's blindness treatment vortigene neparvovec, the first gene therapy likely to reach the US market, in an effort to facilitate development of coverage policies.